Checkout our media coverage, showcased in leading national & international news platforms.
CAR-T Cell Therapy
Harnessing Your Immune System to Fight Cancer Safely
India faces a growing cancer burden, ranking second globally in cancer mortality. For aggressive B-cell malignancies like Acute Lymphoblastic Leukemia (blood cancer) and Large B-cell Lymphoma (lymph node cancer), over 40% of patients relapse or resist chemotherapy and other standard treatments.
ImmunoACT brings revolutionary CAR-T cell therapy for cancer treatment in India, where a patient’s own immune cells are genetically modified to recognize and destroy cancer cells. This groundbreaking approach has demonstrated remarkable improvements in overall survival and offers new hope for patients seeking advanced CAR-T therapy in India with limited treatment options.

Our Pipeline

Our Platform

NexCAR19: The Living Drug
Real Stories of Hope
At ImmunoACT, we believe that every patient story matters. Our CAR-T cell therapies are transforming lives-bringing hope where options were once limited. These powerful testimonials reflect not only the resilience of our patients but also the impact of cutting-edge, gene-modified cell therapy. As we work alongside leading healthcare institutions, academic collaborators, and strategic partners, our mission remains clear: to expand equitable access to advanced immunotherapies and redefine cancer care in India and beyond.
Our Manufacturing Facility
At ImmunoACT, our advanced manufacturing facility is purpose-built to deliver high-quality, safe, and scalable cell and gene therapies. With the capacity to treat up to 750 patients annually, we ensure timely and consistent access to life-saving treatments.
- WHO-Certified GMP Facility: Compliant with global quality and safety standards to ensure purity, consistency, and efficacy in every therapy.
- Scalable Treatment Capacity: Expanding from 750 to 1,500 patients per year to meet growing demand and reduce treatment wait times.
- End-to-End Manufacturing: Fully integrated process from plasmid design to viral vector production and ex-VIVO cell engineering.
- Rapid & Reliable Delivery: Streamlined operations for fast turnaround, ensuring therapies reach patients when they need them most.
- Global-Standard Quality Control: Dedicated QC/QA units to rigorously test and validate each batch before release.
- Clinician-Centric Support: Backed by experts in clinical trials, regulatory affairs, and treatment logistics to simplify doctor workflows.
- Patient-Focused Outcomes: Facility designed with one goal in mind: enabling safe, accessible, and effective therapies for every patient

What is NexCAR19™ ?
NexCAR19™ is a CAR-T cell therapy that involves the genetic modification of your T-cells in a lab, empowering them to identify and destroy specific cancerous B-cells upon re-introduction into the body.
NexCAR19™’s Impact
Total Patients Treated
200+
B-NHL Remission Rate
68%
B-ALL Rate
73%
Vein-To-Vein Time
~20
Longest Remission
2+
Partnered Hospitals
Our strong association with over 80 leading cancer treatment hospitals in India ensures hassle-free treatment with our CAR-T cell therapies.

Media
Gene therapy for blood cancer shows 73 per cent response rate in clinical trials
The Economic Times
17 Mar 2025Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost
Nature
21 May 2024President of India Launches India’s First Home-Grown Gene Therapy for Cancer developed by IIT Bombay, Tata Memorial Centre and ImmunoACT
Press Information Bureau (PIB)
04 Apr 2024Publications
Read our publications, published in prestigious journals such as The Lancet Haematology, Molecular Cancer Therapeutics by AACR and Blood by the American Society of Hematology.
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
Article
Apr 24, 2025Talicabtagene Autoleucel for Relapsed or Refractory B-cell Malignancies: Results from an Open-label, Multicentre, Phase 1/2 Study
Article
Apr 1, 2025Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Abstract
Dec 9, 2023Stories of Hope
Real Stories of Hope


Ramnath Vishnu
Cancer Survivor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer leo enim, fringilla sit amet massa vitae, faucibus consectetur neque…


Ramnath Vishnu
Cancer Survivor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer leo enim, fringilla sit amet massa vitae, faucibus consectetur neque…


Ramnath Vishnu
Cancer Survivor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer leo enim, fringilla sit amet massa vitae, faucibus consectetur neque…
Frequently Asked Questions
View All FAQsHarnessing Your Immune System to Fight Cancer Safely
Begin Your Personalized Cancer Treatment Journey
